Press release
Leading Growth Driver in the Febrile Neutropenia Market in 2025: Rising Cancer Prevalence Fueling Growth In The Market Driver's Influence
Febrile Neutropenia
The increasing prevalence of cancer is expected to propel the growth of the febrile neutropenia market. Cancer, with its complex causes such as aging, environmental exposure, and genetic factors, is becoming more common worldwide. Febrile neutropenia, which often occurs in cancer patients undergoing chemotherapy, involves a weakened immune system and a higher risk of infections. Targeted treatments for febrile neutropenia help prevent life-threatening infections and allow cancer therapies to proceed safely. For instance, the American Cancer Society projected 1.9 million new cancer cases and 609,360 cancer-related deaths in 2022 in the U.S., which is fueling the demand for febrile neutropenia treatments.
Get Your Febrile Neutropenia Market Report Here:
https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report
How will the growth rate of the febrile neutropenia market shape industry trends by 2034?
The febrile neutropenia market has shown strong growth, increasing from $10.60 billion in 2024 to $11.31 billion in 2025 at a CAGR of 6.7%. The historical growth has been driven by the rising incidence of cancer, increased adoption of chemotherapy, expansion of personalized medicine, reduced healthcare costs, and a growing prevalence of neutropenia.
The febrile neutropenia market is projected to expand significantly, reaching $14.48 billion by 2029 at a CAGR of 6.4%. Growth will be driven by the increasing use of immunosuppressive drugs, rising research and development activities, favorable reimbursement policies, higher investment levels, and a growing incidence of leukemia. Key trends include rapid molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, advancements in immunotherapy and targeted treatments, improved risk stratification models, and progress in fungal biomarker technology.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp
What trends are poised to drive the future success of the febrile neutropenia market?
In the febrile neutropenia market, companies are focused on developing biosimilar drugs to improve treatment accessibility and reduce costs. Biosimilars are biologics that closely resemble approved reference drugs in structure, function, and efficacy, providing cost-effective alternatives to original biologics. In September 2022, Fresenius Kabi, a Germany-based pharmaceutical company, received FDA approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This biosimilar is intended for patients with non-myeloid malignancies undergoing chemotherapy, which can cause febrile neutropenia, a condition characterized by low white blood cell counts and fever. The approval of Stimufend helps make treatment more accessible while providing a cost-effective option for patients undergoing chemotherapy. Fresenius Kabi plans to launch Stimufend in a prefilled syringe format and is also developing an on-body injector for future use, improving the overall patient experience.
Which primary segments of the febrile neutropenia market are driving growth and industry transformations?
The febrile neutropenia market covered in this report is segmented -
1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration
Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187
Which geographical regions are pioneering growth in the febrile neutropenia market?
North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the influential players reshaping the febrile neutropenia market landscape?
Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp
What Is Covered In The Febrile Neutropenia Global Market Report?
•Market Size Forecast: Examine the febrile neutropenia market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the febrile neutropenia market for a structured understanding.
•Key Players Overview: Analyze major players in the febrile neutropenia market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the febrile neutropenia market.
•Segment Contributions: Evaluate how different segments drive overall growth in the febrile neutropenia market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the febrile neutropenia market.
•Industry Challenges: Identify potential risks and obstacles affecting the febrile neutropenia market.
•Competitive Landscape: Review strategic developments in the febrile neutropenia market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Growth Driver in the Febrile Neutropenia Market in 2025: Rising Cancer Prevalence Fueling Growth In The Market Driver's Influence here
News-ID: 3934472 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Neutropenia
Global Neutropenia Market Poised for Significant Growth
Full Report: https://www.alliedmarketresearch.com/neutropenia-treatment-market-A06298
The global neutropenia market is witnessing notable expansion, driven by rising cancer prevalence, innovative treatment developments, and increasing adoption of biosimilars. According to industry reports, the market was valued at $12.6 billion in 2019 and is projected to reach $19.3 billion by 2027, growing at a CAGR of 5.4%.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A06298
Understanding Neutropenia
Neutropenia is a medical condition characterized by a deficiency of neutrophils, a…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Biologic Drug Treatments for Neutropenia: Market Trends 2024
"The Business Research Company recently released a comprehensive report on the Global Neutropenia Biologic Drug Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
"Revolutionary Advances in Neutropenia Treatment: A Booming Market Opportunity"
𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐧𝐞𝐮𝐭𝐫𝐨𝐩𝐞𝐧𝐢𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $12,602.5 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2019, 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $19,303.1 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2027, 𝐰𝐢𝐭𝐡 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 5.4% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.
Neutropenia is a condition characterized by a low count of neutrophils, a type of white blood cell that helps fight infections. The treatment of neutropenia depends on the underlying cause and severity of the condition. Here are some common treatments…
